A23K20/153

Compositions and methods for treating viral infections in shrimps

Nanoparticles comprising partially deacetylated chitosan and ss or dsRNA partially complementary to, binding to or at least 90% identical to mRNA targets of viruses pathogenic in farmed crustaceans, compositions and farmed aquatic crustaceans comprising the same, and methods for their use in treating or preventing viral infection in aquaculture are provided.

Bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage CJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage CJ24 (KCCM11462P) or the composition.

Bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage CJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage CJ24 (KCCM11462P) or the composition.

Fish Attractants
20210045413 · 2021-02-18 ·

Fish attractants comprising amino acids and nucleoside compounds which are useful in attracting fish to aquaculture feed as used in commercial fish farming and to lures and baits used in sport fishing. The fish attractants can be applied as a coating on or incorporated into the bulk of the feed, lures or feed.

Fish Attractants
20210045413 · 2021-02-18 ·

Fish attractants comprising amino acids and nucleoside compounds which are useful in attracting fish to aquaculture feed as used in commercial fish farming and to lures and baits used in sport fishing. The fish attractants can be applied as a coating on or incorporated into the bulk of the feed, lures or feed.

TRANSGENIC MICROALGAE AND USE THEREOF AS A FEED FOR DELIVERY OF INTERFERING RNA MOLECULES
20210032625 · 2021-02-04 · ·

The present invention provides non-propagating transgenic microalgae expressing at least one heterologous RNAi molecule. The RNAi-expressing non-propagating transgenic microalgae are used for oral delivery of the RNAi molecule to a target organism in its intact and functional form. The heterologous RNAi molecule, present within the microalgae, is characterized by being biologically active, exerting at least one specific effect on the organism consuming the microalgae or on a pathogen of said organism. In particular, the non-propagating transgenic microalgae are used as agents for biological control of animal and plant pests.

TRANSGENIC MICROALGAE AND USE THEREOF AS A FEED FOR DELIVERY OF INTERFERING RNA MOLECULES
20210032625 · 2021-02-04 · ·

The present invention provides non-propagating transgenic microalgae expressing at least one heterologous RNAi molecule. The RNAi-expressing non-propagating transgenic microalgae are used for oral delivery of the RNAi molecule to a target organism in its intact and functional form. The heterologous RNAi molecule, present within the microalgae, is characterized by being biologically active, exerting at least one specific effect on the organism consuming the microalgae or on a pathogen of said organism. In particular, the non-propagating transgenic microalgae are used as agents for biological control of animal and plant pests.

<i>Vibrio parahaemolyticus </i>bacteriophage Vib-PAP-5 and use thereof for suppressing proliferation of <i>Vibrio parahaemolyticus </i>bacteria

The present invention relates to a Myoviridae bacteriophage Vib-PAP-5 (accession number KCTC 13029BP) isolated from nature characterized by having a capability for specifically killing Vibrio parahaemolyticus bacteria and having a genome expressed by the SEQ ID NO:1, and to a method for preventing and treating infections from Vibrio parahaemolyticus bacteria by means of a composition comprising the Myoviridae bacteriophage Vib-PAP-5 as an active ingredient.

<i>Vibrio parahaemolyticus </i>bacteriophage Vib-PAP-5 and use thereof for suppressing proliferation of <i>Vibrio parahaemolyticus </i>bacteria

The present invention relates to a Myoviridae bacteriophage Vib-PAP-5 (accession number KCTC 13029BP) isolated from nature characterized by having a capability for specifically killing Vibrio parahaemolyticus bacteria and having a genome expressed by the SEQ ID NO:1, and to a method for preventing and treating infections from Vibrio parahaemolyticus bacteria by means of a composition comprising the Myoviridae bacteriophage Vib-PAP-5 as an active ingredient.

Method using slit-robo system to treat sarcopenia
10897923 · 2021-01-26 · ·

The present invention relates to a method using a SLIT-ROBO system to treat sarcopenia and, more specifically, to a method comprising administration of a gene selected from among slit1, slit2, slit3, robo1, robo2, and fragments thereof, or a protein expressed from the gene as an effective method for treating a muscle disease or for improving muscular function.